HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.

Smith I, Chua S: Medical treatment of early breast cancer. III: chemotherapy. BMJ (Clinical research ed. 2006, 332: 161-162. 10.1136/bmj.332.7534.161.

Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005, 23: 8597-8605. 10.1200/JCO.2005.02.5841.

Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Journal of the National Cancer Institute. 2007, 99: 196-205. 10.1093/jnci/djk028.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist. 2009, 14: 320-368. 10.1634/theoncologist.2008-0230.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY. 1987, 235: 177-182. 10.1126/science.3798106.

Jarvinen TA, Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Current cancer drug targets. 2006, 6: 579-602. 10.2174/156800906778742497.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN: HER2 and response to paclitaxel in node-positive breast cancer. The New England journal of medicine. 2007, 357: 1496-1506. 10.1056/NEJMoa071167.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute. 2008, 100: 14-20. 10.1093/jnci/djm252.

Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH: HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001, 12: 1081-1089. 10.1023/A:1011669223035.

Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D: Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Journal of the National Cancer Institute. 2004, 96: 1141-1151. 10.1093/jnci/djh198.

Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry. 2001, 70: 369-413. 10.1146/annurev.biochem.70.1.369.

Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG: A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (New York, NY. 2006, 312: 1798-1802. 10.1126/science.1127196.

Hicks DG, Tubbs RR: Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human pathology. 2005, 36: 250-261. 10.1016/j.humpath.2004.11.010.

Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, Gerber B, Braun S, Sommer H, Friese K: Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?. Journal of cancer research and clinical oncology. 2005, 131: 539-546. 10.1007/s00432-005-0683-y.

Lambros MB, Natrajan R, Reis-Filho JS: Chromogenic and fluorescent in situ hybridization in breast cancer. Human pathology. 2007, 38: 1105-1122. 10.1016/j.humpath.2007.04.011.

Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP: Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005, 16: 1762-1771. 10.1093/annonc/mdi366.

Pritchard KI: Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?. J Clin Oncol. 2009, 27: 3875-3876. 10.1200/JCO.2009.22.8361.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine. 1998, 4: 844-847. 10.1038/nm0798-844.

Skacel M, Skilton B, Pettay JD, Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol. 2002, 10: 1-6. 10.1097/00022744-200203000-00001.

Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G: Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009, 76: 275-285. 10.1159/000207504.

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. The American journal of pathology. 2000, 157: 1467-1472. 10.1016/S0002-9440(10)64785-2.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of pathology & laboratory medicine. 2007, 131: 18-43.

Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL: RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem. 2009, 55: 1719-1727. 10.1373/clinchem.2008.122572.

Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W: Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clinical chemistry. 2010, 56: 1845-1853. 10.1373/clinchem.2010.151233.

Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ: Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol. 2011, 20: 1-10. 10.1097/PDM.0b013e3181e3630c.

Bhargava R, Lal P, Chen B: HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. American journal of clinical pathology. 2005, 123: 889-895. 10.1309/PCFK8YTQPYWD534F.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 2009, 101: 736-750. 10.1093/jnci/djp082.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007, 25: 2127-2132. 10.1200/JCO.2006.10.3523.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast cancer research and treatment. 2006, 100: 229-235. 10.1007/s10549-006-9242-8.

Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute. 2009, 101: 1446-1452. 10.1093/jnci/djp335.

Nielsen KV, Muller S, Moller S, Schonau A, Balslev E, Knoop AS, Ejlertsen B: Aberrations of ERBB2 and TOP2A genes in breast cancer. Molecular oncology. 2010, 4: 161-168. 10.1016/j.molonc.2009.11.001.

De P, Smith BR, Leyland-Jones B: Human epidermal growth factor receptor 2 testing: where are we?. J Clin Oncol. 2010, 28: 4289-4292. 10.1200/JCO.2010.29.5071.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B: Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human pathology. 2010, 41: 103-106. 10.1016/j.humpath.2009.07.001.

Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, Hellwig B, Rahnenfuhrer J, Hengstler JG, Gehrmann MC: ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010, 16: 2391-2401. 10.1158/1078-0432.CCR-09-2471.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Ruschoff J: Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007, 9: R68-10.1186/bcr1776.

Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol. 2010, 23: 62-70. 10.1038/modpathol.2009.136.

Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW: Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). The lancet oncology. 2010, 11: 266-274. 10.1016/S1470-2045(10)70006-1.

Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, chromosomes & cancer. 1999, 26: 142-150. 10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B.

Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS: Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. Journal of hematology & oncology. 2008, 1: 12-10.1186/1756-8722-1-12.

Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011, 29: 859-867. 10.1200/JCO.2009.27.5644.

Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003, 39: 631-634. 10.1016/S0959-8049(02)00745-1.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. Journal of the National Cancer Institute. 2009, 101: 644-650. 10.1093/jnci/djp067.

Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brunner N: HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 2010, 28: 984-990. 10.1200/JCO.2009.24.1166.

Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B: Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011, 29: 1578-1586. 10.1200/JCO.2010.31.2231.

Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009, 22: 1169-1175. 10.1038/modpathol.2009.78.

Moelans CB, de Weger RA, Van der Wall E, van Diest PJ: Current technologies for HER2 testing in breast cancer. Critical reviews in oncology/hematology. 2011

Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD: Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002, 8: 1061-1067.

Mueller RE, Parkes RK, Andrulis I, O'Malley FP: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes, chromosomes & cancer. 2004, 39: 288-297. 10.1002/gcc.20008.

Romero A, Martin M, Cheang MC, Lopez Garcia-Asenjo JA, Oliva B, He X, de la Hoya M, Garcia Saenz JA, Arroyo Fernandez M, Diaz Rubio E: Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. The American journal of pathology. 2011, 178: 1453-1460. 10.1016/j.ajpath.2010.12.042.

Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. British journal of cancer. 1996, 73: 1518-1524. 10.1038/bjc.1996.286.

Stacey DW, Hitomi M, Chen G: Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Molecular and cellular biology. 2000, 20: 9127-9137. 10.1128/MCB.20.24.9127-9137.2000.

Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic acids research. 1996, 24: 4464-4470. 10.1093/nar/24.22.4464.

Stros M, Polanska E, Struncova S, Pospisilova S: HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. Nucleic acids research. 2009, 37: 2070-2086. 10.1093/nar/gkp067.

Goswami PC, Sheren J, Albee LD, Parsian A, Sim JE, Ridnour LA, Higashikubo R, Gius D, Hunt CR, Spitz DR: Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. The Journal of biological chemistry. 2000, 275: 38384-38392.

Beresford MJ, Wilson GD, Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006, 8: 216-10.1186/bcr1618.

Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nature reviews. 2009, 9: 327-337. 10.1038/nrc2608.

Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP: Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer. 2006, 42: 2954-2960. 10.1016/j.ejca.2006.06.013.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology. 2010, 11: 174-183. 10.1016/S1470-2045(09)70262-1.

Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast cancer research and treatment. 2009, 113: 457-466. 10.1007/s10549-008-9964-x.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. International journal of oncology. 2004, 24: 201-209.

Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. 2009, 9: 338-350.

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B: retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005, 23: 7483-7490. 10.1200/JCO.2005.11.007.

Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG: Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 2009, 15: 2711-2722. 10.1158/1078-0432.CCR-08-1878.

Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast (Edinburgh, Scotland). 2007, 16: 86-93. 10.1016/j.breast.2006.06.008.

Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G: Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. British journal of cancer. 2008, 99: 1775-1785. 10.1038/sj.bjc.6604769.

Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF: Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009, 27: 4287-4292. 10.1200/JCO.2008.21.6887.

Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechere L, Reed JC: BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010, 16: 3988-3997. 10.1158/1078-0432.CCR-10-0079.

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller BM, Steffen J, von Toerne C, Wirtz R, Baumann I: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial ( NCT00544765 ). Breast cancer research and treatment. 2011, 126: 109-117. 10.1007/s10549-010-1316-y.

Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger GP, Hellborg H, Bjohle J, Borg AL: Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol. 2007, 18: 845-850. 10.1093/annonc/mdm059.

Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. American journal of clinical pathology. 2008, 129: 563-570. 10.1309/1AKQDQ057PQT9AKX.

Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical chemistry. 2007, 53: 1084-1091. 10.1373/clinchem.2006.076497.